Philip Breitfeld MD
Managing Director, The Breitfeld Group, LLC
Join to View Full Profile
2115 Meadowcreek DrDurham, NC 27705
Dr. Breitfeld is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Education & Training
Boston Children’s Hospital/Boston Medical CenterFellowship, Pediatric Hematology/Oncology, 1982 - 1985
University of Rochester Medical CenterResidency, Pediatrics, 1979 - 1982
University of Rochester School of Medicine and DentistryClass of 1979
Princeton UniversityAB, Chemistry, 1971 - 1975
Certifications & Licensure
American Board of Pediatrics Pediatrics
Awards, Honors, & Recognition
- Whos Who in Medicine and Healthcare Marquis Whos Who
Clinical Trials
- Comparison of Chemotherapy Regimens in Treating Children With Relapsed or Progressive Rhabdomyosarcoma Start of enrollment: 2001 Nov 01
Publications & Presentations
PubMed
- 28 citationsRisk‐based treatment for patients with first relapse or progression of rhabdomyosarcoma: A report from the Children's Oncology GroupLeo Mascarenhas, Elizabeth R. Lyden, Philip P. Breitfeld, David O. Walterhouse, Sarah S. Donaldson
Cancer. 2019-08-01 - 70 citationsFactors associated with failure of oncology drugs in late-stage clinical development: A systematic reviewDenis Leonardo Fontes Jardim, Eric S. Groves, Philip P. Breitfeld, Razelle Kurzrock
Cancer Treatment Reviews. 2017-01-01 - 76 citationsRandomized Phase II Window Trial of Two Schedules of Irinotecan With Vincristine in Patients With First Relapse or Progression of Rhabdomyosarcoma: A Report From the C...Leo Mascarenhas, Elizabeth Lyden, Philip P. Breitfeld, David O. Walterhouse, Sarah S. Donaldson
Journal of Clinical Oncology. 2010-10-20
Press Mentions
- Fannin/Allterum Awarded $2 Million SBIR Phase II Grant from NIH to Advance Monoclonal Antibody for Treating Childhood LeukemiaMay 8th, 2023
Champions Oncology Reports 50% Revenue Growth, Accelerated Progress on Path to Profitability and Future Role Changes of the Senior LeadershipNovember 29th, 2016
Grant Support
- Early clinical development of a novel IL-7R antibody for treating children with relapsed T-cell leukemiaFANNIN PARTNERS, LLC2022–2026
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
